FDA authorizes COVID-19 point-of-care test

The Food and Drug Administration last week issued an emergency use authorization for Cue Health Inc.’s new SARS-CoV-2 nasal swab test in patient care settings.

Point-of-care tests eliminate the need for off-site lab testing, and instead allow patient settings, like hospitals and emergency departments, to produce results and provide patients with more immediate access to those test results.